Malignant Carcinoid Syndrome Differential Diagnoses

1. Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020 Mar 5. 12 (3):e7186. [Medline]. [Full Text].

2. Clement D, Ramage J, Srirajaskanthan R. Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. J Oncol. 2020. 2020:8341426. [Medline]. [Full Text].

3. Pandit S, Annamaraju P, Bhusal K. Carcinoid Syndrome. 2020 Jan. [Medline]. [Full Text].

4. Ahlman H. Midgut carcinoid tumors. Surg Annu. 1986. 18:65-93. [Medline].

5. Papadogias D, Makras P, Kossivakis K, et al. Carcinoid syndrome and carcinoid crisis secondary to a metastatic carcinoid tumour of the lung: a therapeutic challenge. Eur J Gastroenterol Hepatol. 2007 Dec. 19(12):1154-9. [Medline].

6. Bonaros N, Muller S, Bonatti J, et al. Primary ovarian carcinoid heart disease curatively treated with a two-stage procedure. Thorac Cardiovasc Surg. 2007 Oct. 55(7):467-9. [Medline].

7. Chaowalit N, Connolly HM, Schaff HV, et al. Carcinoid heart disease associated with primary ovarian carcinoid tumor. Am J Cardiol. 2004 May 15. 93(10):1314-5. [Medline].

8. Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S. Carcinoid Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol. 2019 Jul 9. 20 (9):70. [Medline].

9. Lubarsch O. Ueber den primaren Krebs des Ileum, nebst Bemerhunge uber das gleichzeitge Vorkommen von Krebs und Tuberculose. Virchows Arch. 1888. 111:280-317.

10. Oberndorfer S. Uber die "kleinen Dunndarm Carcinome". Verh Dtsch Ges Pathol. 1907. 11:113—6.

11. Erspamer V, Asero B. Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-Hydroxytryptamine. Nature. 1952. 169:800-1.

12. Gosset A, Masson P. Tumeurs endocinne de l'appendice. Presse Med. 1914. 22:237-40.

13. Masson, P. Carcinoids (argentaffin-cell tumors) and nerve hyperplasia of appendicular mucosa. Am J Patholol. 1928. 4:181-212.

14. Bhattacharyya S, Davar J, Dreyfus G, et al. Carcinoid heart disease. Circulation. 2007 Dec 11. 116(24):2860-5. [Medline].

15. Cunningham JL, Janson ET, Agarwal S, Grimelius L, Stridsberg M. Tachykinins in endocrine tumors and the carcinoid syndrome. Eur J Endocrinol. 2008 Sep. 159(3):275-82. [Medline].

16. Russo S, Boon JC, Kema IP, Willemse PH, den Boer JA, Korf J, et al. Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation. Psychosom Med. 2004 May-Jun. 66(3):422-5. [Medline]. [Full Text].

17. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, et al. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer. 2008 Jul. 47(7):591-603. [Medline].

18. Key Statistics About Gastrointestinal Carcinoid Tumors. American Cancer Society. Available at https://www.cancer.org/cancer/gastrointestinal-carcinoid-tumor/about/key-statistics.html. September 24, 2018; Accessed: August 3, 2021.

19. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001 Sep. 12(9):1295-300. [Medline]. [Full Text].

20. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976 Jul. 84(4):322-30. [Medline].

21. Wilson HM. Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report. Cases J. 2009 Jan 22. 2(1):78. [Medline]. [Full Text].

22. Metcalfe DD. Differential diagnosis of the patient with unexplained flushing/anaphylaxis. Allergy Asthma Proc. 2000. 21(1):21-4. [Medline].

23. Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol. 2006. 7(2):71-84. [Medline].

24. Bhattacharyya S, Toumpanakis C, Caplin ME, et al. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am J Cardiol. 2008 Feb 1. 101(3):378-81. [Medline].

25. Monsegu J, Algayres JP, Ciribilli JM, et al. [Tricuspid insufficiency disclosing carcinoid syndrome]. Rev Med Interne. 1994. 15(9):593-6. [Medline].

26. Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005 Oct. 100(10):2307-14. [Medline].

27. Banzali FM Jr, Tiwari AK, Frantz R, et al. Valvular heart disease caused by carcinoid syndrome: emphasis on the use of intraoperative transesophageal echocardiography. J Cardiothorac Vasc Anesth. 2007 Dec. 21(6):855-7. [Medline].

28. Granerus G, Lindell SE, Waldenstrom J, et al. Histamine metabolism in carcinoidosis. Lancet. 1966 Jun 4. 1(7449):1267-8. [Medline].

29. Campana D, Nori F, Piscitelli L, Morselli-Labate AM, Pezzilli R, Corinaldesi R, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors?. J Clin Oncol. 2007 May 20. 25(15):1967-73. [Medline].

30. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008 Oct 1. 102(7):938-42. [Medline].

31. Sinzinger H, Renner F, Granegger S. Unsuccessful iodine-131 MIBG imaging of carcinoid tumors and apudomas. J Nucl Med. 1986 Jul. 27(7):1221-2. [Medline].

32. Bastarrika G, Cao MG, Cano D, et al. Magnetic resonance imaging diagnosis of carcinoid heart disease. J Comput Assist Tomogr. 2005 Nov-Dec. 29(6):756-9. [Medline].

33. Garg S, Bourantas CV, Nair RK, Alamgir F. Carcinoid syndrome diagnosed by echocardiography. Int J Cardiol. 2009 Feb 11. [Medline].

34. de Diego C, Marcos Alberca P, Cabrera JA, et al. Pathognomonic echocardiographic features of carcinoid syndrome. Clin Cardiol. 2006 Mar. 29(3):134. [Medline].

35. [Guideline] NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Version 2.2021 — June 18, 2021; Accessed: August 3, 20201.

36. Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, et al. Neuroendocrine Tumor Diagnosis and Management: ⁶⁸Ga-DOTATATE PET/CT. AJR Am J Roentgenol. 2018 Aug. 211 (2):267-277. [Medline].

37. Sinha V, Dyer P, Shuvro RC, Geh JI, Karandikar S. Case of carcinoid crisis following a fine-needle biopsy of hepatic metastasis. Eur J Gastroenterol Hepatol. 2009 Jan. 21(1):101-3. [Medline].

38. [Guideline] Delle Fave GF, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage J, et al. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016 Jan 19. 87:[Medline]. [Full Text].

39. Joensuu H, Kumpulainen E, Grohn P. Treatment of metastatic carcinoid tumour with recombinant interferon alfa. Eur J Cancer. 1992. 28A(10):1650-3. [Medline].

40. Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb. 30 (1):163-77. [Medline].

41. Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep. 2016 Jan. 18 (1):7. [Medline].

42. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1. 27(28):4656-63. [Medline].

43. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011 Dec 10. 378(9808):2005-12. [Medline].

44. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17. 371 (3):224-33. [Medline]. [Full Text].

45. Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist. 2021 Jul. 26 (7):e1171-e1178. [Medline]. [Full Text].

46. [Guideline] Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jul. 31 (7):844-860. [Medline]. [Full Text].

47. FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets. January 26, 2018; Accessed: October 8, 2020.

48. Strosberg J, et al; NETTER-1 Trial Investigators. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12. 376 (2):125-135. [Medline]. [Full Text].

49. Strosberg JR, Wolin EM, Chasen BA, et al. First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. J Clin Oncol. May 20, 2018. 36, no. 15_suppl:4099-4099.

50. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan. 35 (1):14-23. [Medline].

51. Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, et al. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist. 2019 Jan 16. [Medline].

52. Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, et al. Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol. 1995 Jun. 13 (6):1486-92. [Medline].

53. Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review. Eur J Radiol. 2018 Mar. 100:23-29. [Medline].

54. Ezziddin S, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, et al. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors. J Nucl Med. 2013 Dec. 54 (12):2032-8. [Medline]. [Full Text].

55. Hodul P, Malafa M, Choi J, et al. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006 Jan. 13(1):61-71. [Medline].

56. Eller R, Frazee R, Roberts J. Gastrointestinal carcinoid tumors. Am Surg. 1991 Jul. 57(7):434-7. [Medline].

57. Farndon JR. The carcinoid syndrome: methods of treatment and recent experience with hepatic artery ligation and infusion. Clin Oncol. 1977 Dec. 3(4):365-75. [Medline].

58. Codd JE, Drozda J, Merjavy J. Palliation of carcinoid heart disease. Arch Surg. 1987 Sep. 122(9):1076-7. [Medline].

59. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation. 2007 Dec 11. 116(24):2860-5. [Medline].

60. Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005 Nov 22. 112(21):3320-7. [Medline].

61. Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery. 2008 Oct. 144(4):645-51; discussion 651-3. [Medline].

62. Reuling EMBP, Dickhoff C, Plaisier PW, Bonjer HJ, Daniels JMA. Endobronchial and surgical treatment of pulmonary carcinoid tumors: A systematic literature review. Lung Cancer. 2019 Aug. 134:85-95. [Medline]. [Full Text].

63. Bernheim AM, Connolly HM, Rubin J, Møller JE, Scott CG, Nagorney DM, et al. Role of hepatic resection for patients with carcinoid heart disease. Mayo Clin Proc. 2008 Feb. 83(2):143-50. [Medline].

64. Shen C, Shih YC, Xu Y, Yao JC. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis. Cancer. 2014 Jul 1. 120(13):2039-49. [Medline].

65. Gregor M. Therapeutic principles in the management of metastasising carcinoid tumors: drugs for symptomatic treatment. Digestion. 1994. 55 Suppl 3:60-3. [Medline].

66. Isenberg-Grzeda E, MacGregor M, Bergel A, Eagle S, Espi Forcen F, Mehta R, et al. Antidepressants appear safe in patients with carcinoid tumor: Results of a restrospective review. Eur J Surg Oncol. 2018 Jun. 44 (6):744-749. [Medline].

67. van der Horst-Schrivers AN, Wymenga AN, Links TP, et al. Complications of midgut carcinoid tumors and carcinoid syndrome. Neuroendocrinology. 2004. 80 Suppl 1:28-32. [Medline].

68. Kleyn CE, Lai-Cheong JE, Bell HK. Cutaneous manifestations of internal malignancy: diagnosis and management. Am J Clin Dermatol. 2006. 7(2):71-84. [Medline].

69. Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (includingcarcinoid) tumours. Gut. 2005 Jun. 54 Suppl 4:iv:1-16. [Medline].

Luigi Santacroce, MD Assistant Professor, Medical School, State University at Bari, Italy

Disclosure: Nothing to disclose.

Laura Diomede University of Bari School of Medicine, Italy

Disclosure: Nothing to disclose.

Lodovico Balducci, MD Professor, Oncology Fellowship Director, Department of Internal Medicine, Division of Adult Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine

Lodovico Balducci, MD is a member of the following medical societies: American Association for the Advancement of Science, American Association for Cancer Research, American College of Physicians, American Geriatrics Society, American Society of Hematology, New York Academy of Sciences, American Society of Clinical Oncology, Southern Society for Clinical Investigation, International Society for Experimental Hematology, American Federation for Clinical Research, American Society of Breast Disease

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

N Joseph Espat, MD, MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral and Enteral Nutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Central Surgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, The Scientific Research Honor Society, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal and Endoscopic Surgeons, Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association, Surgical Infection Society

Disclosure: Nothing to disclose.

Sanjiv S Agarwala, MD Chief of Oncology and Hematology, St Luke's Cancer Center, St Luke's Hospital and Health Network; Professor, Temple University Shool of Medicine

Sanjiv S Agarwala, MD is a member of the following medical societies: American Association for Cancer Research, American Head and Neck Society, European Society for Medical Oncology, American Society of Clinical Oncology, Eastern Cooperative Oncology Group

Disclosure: Received honoraria from BMS for speaking and teaching; Received consulting fee from Novartis for consulting; Received consulting fee from Merck for consulting.

• Print this section
• Print the entire contents of
• Print the entire contents of article